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T
he prevalence of marijuana abuse and dependence disorders has been increasing among adults and adolescents in the
United States. This paper reviews the problems associated with marijuana use, including unique characteristics of mari-
juana dependence, and the results of laboratory research and treatment trials to date. It also discusses limitations of current
knowledge and potential areas for advancing research and clinical intervention.
Marijuana Dependence and Its Treatment 
M
arijuana remains the most widely used illicit substance in the United
States and Europe (European Monitoring Centre for Drugs and
Drug Addiction, 2006; Substance Abuse and Mental Health Services
Administration (SAMHSA), 2007). Although some people question the concept
of marijuana dependence or addiction, diagnostic, epidemiological, laboratory,
and clinical studies clearly indicate that the condition exists, is important, and
causes harm (Budney, 2006; Budney and Hughes, 2006; Copeland, 2004; Roffman
and Stephens, 2006). Marijuana dependence as experienced in clinical popula-
tions appears very similar to other substance dependence disorders, although it is
likely to be less severe. Adults seeking treatment for marijuana abuse or depend-
ence average more than 10 years of near-daily use and more than six serious attempts
at quitting (Budney, 2006; Copeland et al., 2001; Stephens et al., 2002). They
continue to smoke the drug despite social, psychological, and physical impair-
ments, commonly citing consequences such as relationship and family problems,
guilt associated with use of the drug, financial difficulties, low energy and self-
esteem, dissatisfaction with productivity levels, sleep and memory problems, and
low life satisfaction (Gruber et al., 2003; Stephens et al., 2002). Most perceive
themselves as unable to stop, and most experience a withdrawal syndrome upon
cessation.
Approximately half of the individuals who enter treatment for marijuana use
are under 25 years of age. These patients report a distinctive profile of associated
problems, perhaps due to their age and involvement in other risky behaviors (Tims
et al., 2002). Adolescents who smoke marijuana are at enhanced risk of adverse
health and psychosocial consequences, including sexually transmitted diseases and
pregnancy, early school dropout, delinquency, legal problems, and lowered edu-
cational and occupational aspirations.
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Blacksburg, VirginiaSome 4.3 percent of Americans have been depend-
ent on marijuana, as defined in the Diagnostic and
Statistical Manual of Mental Disorders, 4th Edition, Text
Revision(DSM-IV-TR; American Psychiatric Association,
2000), at some time in their lives. Marijuana produces
dependence less readily than most other illicit drugs.
Some 9 percent of those who try marijuana develop
dependence compared to, for example, 15 percent of
people who try cocaine and 24 percent of those who try
heroin. However, because so many people use marijuana,
cannabis dependence is twice as prevalent as depend-
ence on any other illicit psychoactive substance (cocaine,
1.8 percent; heroin, 0.7 percent; Anthony and Helzer,
1991; Anthony, Warner, and Kessler, 1994).
During the past decade, marijuana use disorders have
increased in all age groups. Contributing factors may
include the availability of higher potency marijuana and
the initiation of use at an earlier age. Among adults, mar-
ijuana use disorders increased despite stabilization of
rates of use. An increased prevalence of disorders among
young adult African-American and Hispanic men and
African-American women appears to account for the
overall rise among youth (Compton, 2004). The rea-
sons for the upward trend in disorders among minority
young people are not clear. Speculation has pointed to
the deleterious effects of acculturation on Hispanic youth;
growing numbers of minority youth attending college,
where they may experience increased exposure to mar-
ijuana use; and environmental and economic factors.
For example, young people may turn to marijuana abuse
when they have difficulty obtaining tobacco and alco-
hol, and recent higher prices and stricter governmen-
tal policies may restrict minorities’ more than Caucasians’
access to legal psychoactive substances.
Paralleling the rise in marijuana use disorders, treat-
ment admissions for primary marijuana dependence
have increased both in absolute numbers and as a per-
centage of total admissions, from 7 percent in 1993 to
16 percent in 2003 (SAMHSA, 2004). The extent of
marijuana use and its associated consequences clearly
indicate a public health problem that requires system-
atic effort focused on prevention and intervention.
TREATMENT EFFICACY RESEARCH
Systematic research on psychosocial treatments for mar-
ijuana abuse or dependence began approximately 20
years ago, yet the number of controlled studies remains
small. Behavioral treatments, such as motivational
enhancement therapy (MET), cognitive-behavioral 
therapy (CBT), and contingency management (CM),
as well as family-based treatments have been carefully
evaluated and have shown promise. Outpatient treat-
ments for marijuana abuse among adolescents have
recently received increasing attention in the scientific
literature.
Adults
Seven published, randomized efficacy trials for primary
adult marijuana abuse and dependence have consistently
demonstrated that outpatient treatments can reduce
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FIGURE 2. Marijuana accounts for most adolescent drug treatment
admissions and progressively smaller proportions of admissions in
each successive higher age group (SAMHSA, 2006b)
FIGURE 1. The percentage of substance abuse treatment admis-
sions that were due to marijuana nearly doubled from 1993 to 2005
(SAMHSA, 2006b)
R E S E A R C H   R E V I E W — M A R I J U A N A   D E P E N D E N C E   A N D   I T S   T R E A T M E N T   •   5
0
10
20
30
40
50
60
70
35-55 yrs 21-34 yrs 18-20 yrs 12-17 yrs
%
 
o
f
 
a
d
m
i
s
s
i
o
n
s
Alcohol Heroin Marijuana Cocaine6 •   A D D I C T I O N   S C I E N C E   &   C L I N I C A L   P R A C T I C E — D E C E M B E R   2 0 0 7
marijuana consumption and engender abstinence. 
The most commonly tested interventions are adapta-
tions of interventions initially developed to treat alco-
hol or cocaine dependence, in particular MET and CBT
(also known as coping skills training). Recently, trials
have examined the use of CM to enhance the potency
of MET- and CBT-based treatments. The cumulative
findings indicate that (1) each of these interventions rep-
resents a reasonable and efficacious treatment approach;
(2) the combination of MET and CBT is probably more
potent than MET alone; and (3) an intervention that
integrates all three approaches—MET, CBT, and CM—
is most likely to produce positive outcomes, especially
as measured by rates of abstinence from marijuana.
MET addresses ambivalence about quitting and seeks
to strengthen motivation to change. A typical MET reg-
imen consists of one to four 45- to 90-minute individ-
ual sessions. Therapists use a nonconfrontational coun-
seling style to guide the patient toward commitment to
and action toward change. Therapeutic techniques include
using strategic expression of empathy, reflecting, sum-
marizing, affirming, reinforcing self-efficacy, exploring
pros and cons of drug use, rolling with resistance, and
forging goals and plans to achieve them. An online man-
ual, Brief Counseling for Marijuana Dependence,describes
the use of MET intervention with adult marijuana users.
CBT focuses on teaching patients skills relevant to
quitting marijuana and avoiding or managing other
problems that may interfere with good outcomes. Patients
learn functional analysis of marijuana use and cravings,
self-management planning to avoid or cope with drug
use triggers, drug refusal skills, problem-solving skills,
and lifestyle management. CBT for marijuana depend-
ence is typically delivered in 45- to 60-minute, weekly
individual or group counseling sessions; tested CBT
interventions have ranged from 6 to14 sessions. Each
session involves analysis of recent marijuana use or crav-
ings, development of planned responses to situations
that may trigger use or craving, brief training on a
coping skill, role-playing or other interactive exercises,
and practice assignments. Brief Counseling for Marijuana
Dependence describes the content and conduct of
CBT sessions in detail (Steinberg et al., 2005; see “Web
Links to Treatment Manuals”).
A series of four trials demonstrated the efficacy of
both CBT and MET for adult marijuana dependence
(Table 1). After an initial trial showed promising results
for a CBT group intervention (Stephens, Roffman, and
Simpson, 1994), a second trial tested a 14-session group
CBT intervention against 2 individual MET sessions or
a delayed treatment control (DTC) condition (Stephens,
Roffman, and Curtin, 2000). At the 4-month followup,
the CBT and MET groups had achieved significantly
greater rates of abstinence than the DTC group. Days
of use, number of uses per day, dependence symp-
toms, and problems related to use also fell signifi-
cantly compared with those measures in the DTC group,
and gains were generally maintained throughout the 
16-month followup. No significant differences were
observed between CBT and MET conditions on any of
these outcome measures, suggesting that brief motiva-
tional interventions may be as effective as longer CBT
interventions. However, this study confounded treat-
ment modality (group vs. individual) and therapist expe-
rience (provision of MET by more experienced thera-
pists) with treatment length. A similar study showed
that a six-session CBT and a one-session MET treat-
ment, both delivered in individual therapy sessions, pro-
duced greater rates of abstinence than DTC, but again
WEB LINKS TO TREATMENT MANUALS
Adult Treatment Manuals From the Marijuana Treatment Project
Research Group Study (Marijuana Treatment Project Research Group,
2004):
Brief Counseling for Marijuana Dependence (Steinberg et al., 2005)
kap.samhsa.gov/products/brochures/pdfs/bmdc.pdf.
A Community Reinforcement Plus Vouchers Approach: Treating Cocaine
Addiction (Budney and Higgins, 1998)
www.nida.nih.gov/TXManuals/CRA/CRA6.html.
Adolescent Treatment Manuals From the Cannabis Youth Treatment
Study (Dennis et al., 2004):
The Motivational Enhancement Therapy and Cognitive Behavioral Therapy
for Adolescent Cannabis Users: 5 Sessions, Volume 1. NCADI number
BKD384.
The Motivational Enhancement Therapy and Cognitive Behavioral Therapy
Supplement: 7 Sessions of Cognitive Behavioral Therapy for Adolescent
Cannabis Users, Volume 2.
Family Support Network for Adolescent Cannabis Users, Volume 3.
The Adolescent Community Reinforcement Approach for Adolescent
Cannabis Users, Volume 4.
Multidimensional Family Therapy for Adolescent Cannabis Users,Volume 5. 
ncadistore.samhsa.gov/catalog/ProductDetails.aspx?ProductID=15868.
Multisystemic Therapy for Adolescents (Henggeler et al., 2006)
www.mstservices.com.
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little difference was observed between the active treat-
ment groups (Copeland et al., 2001). A positive relation
between therapist experience and outcome was reported
across both treatment conditions.
The most comprehensive trial (n= 450) of MET and
CBT compared nine sessions of combined MET-CBT
with a two-session MET-only intervention and with a
DTC (Marijuana Treatment Project Research Group,
2004). MET-CBT and MET-only again produced bet-
ter abstinence outcomes than DTC. However, in this
trial, MET-CBT was associated with significantly greater
long-term abstinence and greater reductions in frequency
of marijuana use compared with MET alone. Findings
generalized across three sites and were not dependent
on ethnicity or gender. 
In an effort to enhance outcomes further, researchers
have begun to examine the efficacy of CM for treating
marijuana dependence (Budney et al., 2001). The mar-
ijuana CM intervention adapts the abstinence-based
voucher approach originally developed and demon-
strated effective for treating cocaine dependence (Budney
and Higgins, 1998; Higgins et al., 1994). The vouchers
are contingent on marijuana abstinence, confirmed by
twice-weekly drug testing, and their value escalates with
each consecutive negative drug test. Patients exchange
them for prosocial retail items or services that, it is hoped,
will serve as alternatives to marijuana use.
An initial trial of CM for adult marijuana depend-
ence compared a 4-session MET, a 14-session combined
MET-CBT, and a 14-session MET-CBT plus CM (Bud-
ney et al., 2000). Individuals could earn up to $570 in
vouchers if they provided consistently negative urine
samples throughout treatment weeks 3 through 14. The
MET-CBT plus CM condition produced the highest
abstinence rate during treatment. In a second trial con-
ducted to extend these findings (Budney et al., 2006),
90 adults received MET-CBT, MET-CBT plus CM, or
CM alone (no counseling). The magnitude of the CM
incentives was identical to that used in the prior study.
The MET-CBT-alone intervention differed from the
Stephens, Roffman,
and Simpson, 1994
Stephens, Roffman,
and Curtin, 2000
Copeland et al., 2001
Marijuana Treatment
Project Research
Group, 2004
Stephens et al., 2006
Budney et al., 2000
Budney et al., 2006
Kadden et al., 2007
212
291
229
450
87
60
90
240
CBT vs. social support group discus-
sion intervention
14-session CBT group treatment vs.
2-session MET treatment vs. DTC
6-session MET vs. 1-session MET 
vs. DTC
9-session MET-CBT vs. 2-session
MET vs. DTC
9-session MET-CBT vs. 4-session
MET-CBT + pro re nata (PRN; contin-
uing care)
4-session MET vs. 14-session MET-
CBT vs. 14-session MET-CBT + CM
14-session MET-CBT vs. MET-CBT 
+ CM vs. CM alone
9-session MET-CBT vs. MET-CBT +
CM vs. CM alone vs. case manage-
ment
Both groups had significant reductions in marijuana use. No 
significant differences between groups.
Treatment groups showed greater improvement than DTC. No
differences in outcomes between treatment groups.
Both treatment groups reported better outcomes (higher rates 
of abstinence, fewer marijuana-related problems) than DTC.
Both treatment groups reported better outcomes than DTC. 
9-session MET-CBT engendered greater long-term abstinence
and reductions in frequency of use than brief MET.
No between-condition outcome differences observed. Only 
37 percent of PRN subjects used continuing care sessions; sug-
gestive evidence that use of PRN increased abstinence. 
No differences in abstinence between MET and MET-CBT. 
MET-CBT+CM engendered greater abstinence during and at 
the end of treatment than MET or MET-CBT.
Two CM conditions engendered better abstinence outcomes 
during treatment than MET-CBT. MET-CBT+CM had better 
post-treatment abstinence rates than the other groups.
Two CM conditions engendered better abstinence outcomes,
with only the MET-CBT+CM showing superior abstinence rates
during the 1-year followup.
TABLE 1. Randomized Trials for Adult Marijuana Treatment 
CM (Abstinence-Based 
Vouchers)
AUTHOR(S) N INTERVENTION OUTCOME
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initial study in one regard: vouchers ($5) contingent on
providing a urine specimen as scheduled (twice per week)
were provided to ensure equivalent retention and treat-
ment contact. This trial produced three notable out-
comes. First, MET-CBT plus CM and CM alone both
engendered greater initial rates of abstinence than MET-
CBT. Second, MET-CBT plus CM produced outcomes
that were similar to those of CM alone during treatment,
but superior post-treatment. 
A recent study by another research group found sim-
ilar results with a modified CM program (weekly
urine testing, $385 maximum voucher earnings for com-
plete abstinence) in a more diverse (40 percent minor-
ity) and larger sample (n = 240; Kadden et al., 2007).
During 7 weeks of treatment, MET-CBT plus CM and
CM alone produced continuous abstinence outcomes
that were similar to each other and superior to those seen
with MET-CBT. During the following year, the MET-
CBT plus CM patient group sustained overall positive
outcomes somewhat better than those of the CM group,
although differences in abstinence rates were not statis-
tically significant at later followups. As in the previous
CM trials, patients in the CM and non-CM conditions
self-reported similar rates of marijuana use throughout,
illustrating the importance of obtaining subjective
and objective indices of use. In summary, MET, CBT,
and CM each has empirical support for its efficacy, and
CM in combination with MET-CBT has demonstrated
the most potency in outpatient treatment for adult mar-
ijuana dependence, particularly for engendering longer
periods of abstinence. 
Recognizing that many people overcome depend-
ence only after multiple treatment exposures, Stephens
and Roffman (2005) developed and initially tested a cre-
ative, chronic care model of treatment that they termed
“marijuana dependence treatment PRN.” Following an
initial four sessions of MET-CBT, participants were given
the option of determining the number and schedule
of treatment sessions they would attend over a 28-month
period. The comparison condition in this trial was the
same fixed-dose nine-session MET-CBT intervention
used in the large multisite trial mentioned earlier (Mari-
juana Treatment Project Research Group, 2004). There
were three key findings from this trial: (1) A relatively
small percentage of participants (37 percent) made use
of the continuing care sessions, and (2) the PRN con-
dition overall was not more efficacious than the fixed-
dose condition, although (3) the few individuals who
attended the greatest number of continuing care sessions
(mean of 13.4 sessions) had a high level of 90-day absti-
nence (approximately 60 percent) at followup. 
Adolescents and Young Adults
Most information on marijuana treatment efficacy among
young people derives from trials that have included users
of various drugs and have not focused specifically on
marijuana use. Nevertheless, most patients in these stud-
ies have been primary marijuana users. Empirical sup-
port for group or individual CBT and family-based treat-
ments has begun to emerge (Waldron and Kaminer,
2004). The CBT interventions studied have been sim-
ilar to those studied for adults in scope and duration.
Specific forms of family-based treatment that have been
tested include functional family therapy (Waldron et al.,
2001), multidimensional family therapy (MDFT; Liddle
et al., 2001), multisystemic therapy (Henggeler et al.,
2006), family support network intervention (Dennis et
al., 2004), and brief strategic family therapy (Azrin et
al., 1994; Santisteban et al., 2003). Description of these
models is beyond the scope of this paper. However, they
each involve structured, skills-based interventions for
family members and are well described in their respec-
tive manuals. 
The largest clinical trial of outpatient treatment
for adolescent substance abuse focused on marijuana
use (Dennis et al., 2004). Five treatment models were
tested in a multisite study: MET-CBT 5 (2 individual
and 3 group sessions), MET-CBT 12 (2 individual and
10 group sessions), MET-CBT 12 plus family support
network (6 parent education group sessions, 4 home
visits, and case management), the community rein-
forcement approach (10 individual sessions focused on
behavioral change in drug use and lifestyle change, and
4 parent sessions focused on effective parenting, com-
munication, and problem solving), and MDFT (12 to
15 family systems-focused sessions: 6 individual, 3 with
parents alone, and 6 with family). Significant decreases
in drug use and symptoms of dependence were observed
following each of the treatments. However, robust
between-treatment differences in outcomes were not
observed, which unfortunately precludes drawing strong
conclusions about their efficacy. Although results were
promising compared with prior treatment studies, two-
thirds of the youth continued to experience significant 
substance-related symptoms, suggesting that adoles-
cent treatments can be improved and alternative treat-
ment models should be explored (Compton and Pringle,
2004). 
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As they are doing with treatments for adults, researchers
are attempting to enhance youths’ outcomes by adding
a CM intervention to MET-CBT-type interventions.
Positive results were observed in an initial pilot study of
MET-CBT plus a CM intervention that incorporated
an abstinence-based voucher program and parent-based
CM (Kamon, Budney, and Stanger, 2005). The voucher
program was of the same schedule and magnitude as that
used in the previously mentioned adult trials by Budney
and colleagues. However, participants could earn vouch-
ers only if urine toxicology screens were negative for all
drugs tested and if parents reported that, to their knowl-
edge, the adolescent had not used any drugs or alcohol.
The parenting intervention included a contract that
directed parents to provide tangible incentives for absti-
nence and to deliver negative consequences for con-
tinued use. Parents also participated in a weekly behav-
ioral training program called Adolescent Transitions
(Dishion and Kavanagh, 2003), a treatment of choice
for adolescents with conduct disorder. Preliminary data
from an initial randomized trial suggest that the MET-
CBT plus CM improved rates of marijuana absti-
nence and effectively maintained abstinence post-
treatment compared with MET-CBT combined with
weekly parent psychoeducational counseling. The rates
of abstinence achieved appeared greater than those
reported in prior studies; however, comparison across
trials is problematic because of differences in patient
characteristics and differences in the way outcomes are
measured.
Two other tests of CM with adolescents and young
adults have produced promising results. A CM 
abstinence-based voucher program enhanced drug use
outcomes and abstinence when added to a potent out-
patient therapy (i.e., multisystemic therapy) among juve-
nile offenders enrolled in drug court (Henggeler et al.,
2006). Lastly, adding incentives for treatment atten-
dance to MET increased treatment participation by
young adult marijuana abusers involved with the judi-
cial system, but did not lead to increased marijuana absti-
nence (Sinha et al., 2003). In summary, a number of
behaviorally based interventions appear efficacious for
treating adolescent marijuana abuse, and combining
interventions like MET, CBT, CM, and family-based
programs is likely to enhance efficacy.
Effectiveness
Sufficient evidence has accumulated to conclude that
behaviorally based interventions can help many of those
who seek treatment for marijuana use disorders.
Unfortunately, as with treatment for other dependen-
cies, the rates of “success” are modest. Even with MET-
CBT plus CM, the most highly efficacious treatment
for adults, only about one-half of those who enroll in
treatment achieve an initial 2-week period of abstinence,
and among those who do, approximately one-half resume
use within a year (Budney et al., 2006; Kadden et al.,
2007). Across studies, 1-year abstinence rates have ranged
between 19 and 29 percent for MET-CBT, and between
9 and 28 percent for MET. An additional percentage of
adults report a reduction in use and in problems asso-
ciated with use; however, many adults show no evidence
of progress. 
The treatment outcome data for adolescents paint a
similar picture. For example, in the large Cannabis Youth
Treatment study, abstinence rates at the end of treat-
ment were only 11 to 15 percent (Dennis et al., 2004;
see also the preliminary findings of Dennis and colleagues
reported at www.chestnut.org/LI/cyt/findings/index.html),
and rates at 12 months post-treatment, defined by self-
report of no substance use in the prior month, were 17
to 34 percent across the five treatments. Clearly, there
remains much room for improvement in marijuana out-
patient treatment. 
CLINICAL ISSUES
Most clinical issues in treatment for marijuana use dis-
orders parallel those that arise in treatments for other
drug use disorders, though sometimes with distinctive
aspects. Among the clinical features that distinguish mar-
ijuana dependence are the drug’s relatively mild with-
drawal effects and marijuana users’ frequent desire 
to pursue a goal of reducing—rather than abstaining
from—use.
Marijuana as a Secondary Drug of Abuse
In addition to being the illicit drug most commonly used
by the general population, marijuana is also the most
common “other drug” used by those seeking treat-
ment for stimulant or opiate dependence. Such sec-
ondary marijuana use is commonly viewed as a signifi-
cant risk factor for relapse or treatment failure, although
the empirical support for this is equivocal (Epstein
and Preston, 2003).
Many individuals who enter treatment for heroin/opi-
ate dependence or cocaine dependence do not consider
their marijuana use problematic; thus, their readiness
to quit or reduce their marijuana use is low. Some inves-
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tigators have explored CM-based approaches targeting
marijuana use in this clinical population, reasoning that
explicit reinforcement or penalty interventions tied to
marijuana use may motivate and prompt change in indi-
viduals not currently interested in changing. 
Calsyn and Saxon (1999) devised a marijuana CM
program to function as an adjunct to an existing CM
program that required 6 months of urinalysis-confirmed
abstinence from all drugs, except for cannabis, in
order to earn methadone take-home privileges twice a
week. The new intervention simply increased the require-
ment for obtaining twice-weekly take-home status to
include marijuana-negative urinalysis results. In this
small study, 50 percent of the participants responded to
the contingency by stopping their marijuana use, while
the other 50 percent accepted curtailment of their take-
home privileges and continued to use marijuana. 
Kidorf and colleagues (2007) tested a similar “moti-
vated stepped care” approach to reducing cannabis use
in methadone maintenance patients. Fifteen patients
who tested positive only for marijuana during a 6-month
baseline period were informed that, from then on, a pos-
itive test for marijuana (or any other substance) would
increase their counseling requirements from 1 hour per
week to 4. Ten of the patients discontinued marijuana
use when informed about the new counseling rule. The
other five—who were among the heaviest users—con-
tinued to test positive for marijuana and were required
to attend the additional counseling sessions. Of those,
four responded to the intensified counseling, eventually
discontinuing use and returning to the lower-level sched-
ule. One patient did not respond and dropped out of
treatment.
In the cocaine clinic, where many patients do not
endorse a goal of stopping marijuana use, the clinician
must decide how best to approach this issue without
adversely affecting treatment for cocaine dependence
(Budney, Higgins, and Wong, 1996). One study of a
small number of patients explored a sequential strategy
of initially targeting abstinence from cocaine with an
abstinence-based voucher CM program, then targeting
marijuana once cocaine abstinence had been achieved
(Budney et al., 1991). The rationale for this approach
was that the experience of achieving cocaine abstinence
and the associated positive effects might increase aware-
ness of how marijuana use negatively affects a prosocial
lifestyle. Moreover, an initial success with a voucher pro-
gram for cocaine might motivate participation in a sim-
ilar program that targets marijuana. In this study, two
participants quit using cocaine during a 12-week voucher
program, but continued to use marijuana regularly despite
counseling that encouraged abstinence. Both entered
a second 12-week program that required abstinence from
cocaine and marijuana to earn vouchers. Both achieved
abstinence from the two drugs and stayed off cocaine
throughout a 5-month followup period. Unfortunately,
both resumed marijuana use during the followup. 
These studies demonstrate how systematic approaches
to secondary marijuana abuse can be implemented with-
out having significant adverse effects on treatment for
primary opiate or cocaine abuse. Using stepped care or
sequential CM approaches appears effective for initi-
ating abstinence among those ambivalent about stop-
ping their marijuana use. However, longer term con-
tingencies or additional interventions may be needed to
obtain enduring effects (Kidorf et al., 2007). 
Marijuana Withdrawal
As noted earlier, many people question whether one can
truly become dependent on marijuana. The basis for
skepticism is typically doubt that marijuana use can pro-
duce “physiological” dependence—i.e., that cessation
of use produces a withdrawal syndrome. A review of the
literature relevant to this issue is beyond our scope here.
However, research over the past 10 to 15 years has (1)
established a neurobiological basis for a marijuana with-
drawal syndrome via an endogenous cannabinoid sys-
tem in the central nervous system; (2) established the
reliability, validity, and time course of a marijuana with-
drawal syndrome through human laboratory research
and clinical studies; and (3) demonstrated the potential
clinical importance of the withdrawal syndrome (Budney
et al., 2004; Budney and Hughes, 2006). 
The marijuana withdrawal syndrome resembles those
associated with other drugs, particularly tobacco. Patients
experience irritability, anger, depression, difficulty sleep-
ing, craving, and decreased appetite. Many indicate that
these symptoms adversely impact their attempts to quit
and motivate use of marijuana or other drugs for relief
(Copersino et al., 2006). Most symptoms begin within
24 to 48 hours of abstinence, peak within 4 to 6 days,
and last from 1 to 3 weeks, although significant indi-
vidual differences occur in withdrawal expression.
The marijuana withdrawal syndrome does not appear
to include major medical or psychiatric consequences
and may be considered mild compared with heroin and
severe alcohol withdrawal syndromes. Nonetheless, myr-
iad patient reports suggest that additional research to
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understand and develop effective clinical responses to
the withdrawal syndrome may enhance outcomes and
promote successful cessation attempts. 
Pharmacotherapy
To date, a handful of human laboratory studies and one
small clinical trial on potential pharmacotherapies for
marijuana dependence have appeared in the literature
(Hart, 2005). The majority of these efforts have targeted
the marijuana withdrawal syndrome. Bupropion, dival-
proex, naltrexone, nefazodone, and orally administered
∆9-tetrahydrocannabinol (THC) have all been evalu-
ated in studies with marijuana-dependent participants
who were not seeking treatment or planning to quit.
Divalproex has also been evaluated in an outpatient
placebo-controlled trial (Levin et al., 2004). Only orally
given THC and, to a lesser extent, nefazodone have
shown promise. THC reduced craving and ratings of
anxiety, feelings of misery, difficulty sleeping, and chills
(Haney et al., 2004). In addition, participants could not
distinguish active THC from placebo. These findings
were replicated in an outpatient study, which found that
a moderate oral dosage of THC (10 mg, three times
daily) suppressed many marijuana withdrawal symp-
toms and that a higher dosage (30 mg, three times daily)
almost completely abolished withdrawal symptoms
(Budney et al., 2007). Nefazodone decreased ratings
of some withdrawal symptoms (anxiety and muscle pain),
but other ratings (irritability, feelings of misery, and dif-
ficulty sleeping) remained high (Haney et al., 2003).
In summary, the developing literature on pharma-
cotherapy for marijuana dependence supports further
testing of THC, an approach that parallels the use of
agonist medications such as methadone and the nico-
tine patch. Continued exploration of compounds that
target mood, sleep difficulty, craving, and appetite appears
warranted given the potent and reliable symptoms
observed in withdrawal studies. Other promising strate-
gies for pharmacotherapies include targeting the under-
lying physiology of withdrawal—specifically, the decreases
in dopamine activity in the mesolimbic dopamine path-
way—and treating comorbid disorders such as depres-
sion or anxiety. Researchers also are exploring the pos-
sibility of medications to help abstinent individuals avoid
relapse by blocking marijuana’s rewarding effects. One
such compound, the cannabinoid receptor antagonist
SR141617A (rimonabant), has been shown to block the
drug’s subjective and physiological effects (Huestis et
al., 2001).
Tobacco Smoking Among Marijuana Users 
Like users of other drugs of abuse, regular marijuana
users have a higher rate of tobacco use than the general
population; approximately 50 percent of heavy cannabis
users also smoke tobacco (Ford, Vu, and Anthony, 2002;
Moore and Budney, 2001). Moreover, many adolescents
and, to a lesser extent, adults use tobacco and marijuana
together, either mixing the substances, smoking blunts
(hollowed out cigars filled with marijuana), or smoking
one immediately after the other.
At least one study suggests that, among cannabis-
dependent individuals, tobacco smokers have worse psy-
chosocial problems and poorer cannabis cessation out-
comes (Moore and Budney, 2001). Whether this indicates
that treatments for marijuana dependence should simul-
taneously address tobacco smoking is not clear. No clin-
ical studies have focused on this issue. However, research
suggests that treatment that promotes smoking cessa-
tion does not disrupt alcohol abstinence and may actu-
ally enhance the likelihood of longer-term sobriety
(Gulliver, Kamholz, and Helstrom, 2006). 
One laboratory study compared withdrawal symp-
toms during simultaneous cessation of marijuana and
tobacco to withdrawal from each substance alone (Vandrey
et al., 2007). Withdrawal was more severe during simul-
taneous cessation, but the differences were of short dura-
tion and not robust, and substantial individual differ-
ences were noted. Interestingly, five participants rated
dual abstinence as the most difficult of the three condi-
tions; four rated cannabis abstinence and three rated
tobacco abstinence as the most difficult. The reason
simultaneous abstinence was not uniformly experienced
as most severe may be that both substances are smoked.
Individuals quitting one drug might have had withdrawal
intensified by the smoking cues associated with contin-
uing use of the other, while individuals quitting both
were spared such cues.
Should we encourage individuals trying to quit mar-
ijuana use to try also to quit tobacco? Certainly we should
discuss this option with clients, as tobacco abstinence
may make marijuana abstinence easier and increase
chances of maintaining marijuana abstinence for a longer
term. However, as with treatments for other substance
dependence disorders, mandating tobacco cessation as
a treatment goal might create a barrier to treatment seek-
ing or trigger treatment dropout.
Treatment Goals: Abstinence or Moderation?
Because marijuana is perceived as less harmful than
Should we
encourage indi-
viduals 
trying to quit
marijuana 
to also quit
tobacco?1 2 •   A D D I C T I O N   S C I E N C E   &   C L I N I C A L   P R A C T I C E — D E C E M B E R   2 0 0 7
cocaine or heroin, some people suggest that use reduc-
tion, instead of abstinence, may be an acceptable clini-
cal goal. Indeed, many individuals who enter treatment
are ambivalent about giving up marijuana completely.
The only published study (n = 291) that systemati-
cally assessed the goals of adults enrolling in marijuana
treatment reported that 71 percent sought abstinence,
28 percent wanted to moderate their use to 3 days or less
per week, and 1 percent wished only to incur fewer
adverse consequences from their smoking (Lozano,
Stephens, and Roffman, 2006). Patient goals were meas-
ured again at the end of treatment and repeatedly dur-
ing a 12-month followup period. Ultimately, the por-
tion desiring to be abstinent declined to 49 percent,
while those wishing only for fewer negative effects increased
to 26 percent. Most notably, patient goals predicted out-
comes: 40 to 65 percent of those aiming for absti-
nence or moderation had achieved their desired out-
come at the following assessment. The second most
frequent outcome among those with abstinence goals
was moderation, while the second most frequent out-
come among those with moderation goals was contin-
ued problematic use. In summary, abstinence goals pre-
dicted better outcomes. That said, because the focus
of treatment in this study was abstinence, those with
moderation goals were not necessarily provided with
treatment that best matched their goals. 
Little is known about what constitutes nonharm-
ful use of marijuana, and whether and when modera-
tion may be an appropriate clinical goal for treatment.
Clinical epidemiological studies clearly demonstrate that
many individuals experiment with marijuana, and some
even use the drug regularly without reporting signifi-
cant consequences. This finding clearly parallels what is
observed with alcohol use. The sparse data available
on goals discussed earlier are fairly consistent with what
is observed in the alcohol treatment literature—that
is, patients who aim for abstinence appear to obtain bet-
ter outcomes. Some individuals who make moderation
their objective can achieve it, but the likelihood of
failing is greater with this goal. Moderation-focused
treatments for marijuana have yet to be tested. Thus, no
guidelines or predictors exist concerning which patients
might succeed with this approach. Moreover, marijuana’s
illegality complicates any consideration of treatment
goals other than abstinence. 
Early Intervention and Secondary Prevention
Although more people are seeking help for problems
with marijuana today, they still represent only a small
percentage of those who may benefit from treatment.
Of the approximately 4 million persons in the United
States who reported problems consistent with a mari-
juana use disorder in a 2005 survey (SAMHSA, 2006a),
only about 7 to 8 percent received treatment. Adolescents
who report signs of problematic use—a relatively small
percentage—seldom present for treatment. Those
who do almost never self-refer; they are typically “forced”
into treatment by parents, the juvenile justice system,
or their school administration, and most do not admit
that their use is problematic (Diamond et al., 2006).
Responding to this situation, one group of researchers
recently developed “check-up” interventions to reach
marijuana users who have not sought treatment, either
because they are ambivalent about stopping or do not
perceive their use to be a problem, or at least not a prob-
lem severe enough to warrant treatment (Stephens et al.,
2004; Walker et al., 2006).
The Teen Marijuana Check-Up (TMCU), designed
for delivery in high schools, is advertised as an oppor-
tunity to “take stock” of marijuana use and is intended
to facilitate a candid, in-depth evaluation of a teen’s use.
The program features a brief MET intervention, con-
sisting of a computerized assessment and two 30-minute
sessions, which encourages participation by demanding
minimal effort. The program treats adolescents as experts
and decision makers regarding their marijuana use, does
not label marijuana users as having a problem, and views
ambivalence about the drug as normal. An initial ran-
domized trial conducted in four high schools compared
the TMCU with a delayed treatment condition (Walker
et al., 2006). Teens in both conditions significantly
reduced their marijuana use over a 3-month period; how-
ever, no significant between-group differences were
observed. Despite the absence of a clear effect of the
TMCU, this study showed that adolescents using mar-
ijuana would volunteer to participate in an intervention
provided at their school, a response that holds promise
for reducing problematic levels of marijuana use.
A similar Marijuana Check-Up (MCU) for adults
was designed to reach marijuana users who were expe-
riencing adverse consequences, but were ambivalent
about change and not likely to enter treatment (Stephens
et al., 2004). Marijuana users called the clinic in response
to advertisements stating that objective, up-to-date infor-
mation on marijuana use and its effects was available.
Upon contact, callers were told that this was not a treat-
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ment that would then be followed by a one-session per-
sonalized feedback session, a one-session therapist-
guided multimedia session (documentary and slide show
providing objective information on marijuana and its
effects), or a session (MET or multimedia) delayed by
7 weeks. Respondents to the advertisements were near-
daily marijuana users, two-thirds of whom were in the
precontemplation or contemplation stage of change.
Over 12 months, the MCU condition resulted in greater
reductions in marijuana use and in associated problems
than the multimedia condition; however, absolute lev-
els of change were relatively small. Nonetheless, like the
TMCU for adolescents, this study showed that this 
intervention model attracted a “unique” sample of ambiva-
lent marijuana users who may be ideal candidates for
secondary prevention interventions like the MCU.
Continued exploration of more potent MCU models
may yield a method for reaching marijuana users who
would otherwise not contact the typical treatment sys-
tem, at least not at this stage of their use. 
FUTURE DIRECTIONS FOR TREATMENT
RESEARCH
Over the last 15 years, we have witnessed great advances
in the empirical base for treatment approaches to mar-
ijuana use disorders. Clear evidence has accumulated for
the efficacy of behavioral treatments similar to those
used for disorders involving alcohol and other drugs of
abuse. The goals for future research are more potent
treatment approaches and intervention strategies.
A better understanding of the mechanisms of action
of marijuana treatments and predictors of outcome 
will lead, it is hoped, to innovations that can better match
individuals to specific therapeutic modalities or result
in modifications to approaches that deliver more of 
the “active ingredients” necessary for change. For 
example, with CM interventions, factors related to the
frequency, duration, and magnitude of the incentive
schedule used to reinforce abstinence are likely to affect
the potency of the intervention and influence outcome
(Lussier et al., 2006). In addition, researchers need to
continue exploring the potential use of pharmacother-
apies as a primary or secondary treatment approach.
Recent advances in the understanding of the neurobi-
ology of marijuana’s actions make this a very promising
area of investigation. Continued development of cost-
effective interventions remains a priority. Other areas
that warrant focus include continuing care protocols to
prevent or reduce the severity of lapses or relapses, explo-
ration of different magnitude and schedules of rein-
forcement in CM interventions, and use of innovative
technologies—such as computers and the Internet—to
IS MARIJUANA UNIQUE?
A
large part of the general population has had personal experience
with marijuana, and most have not become addicted. Many find it
perplexing to contemplate how someone else could become addicted 
to a drug they themselves have tried and can easily set aside or stop
using. Accordingly, they think marijuana dependence must qualitatively
differ from dependence on other drugs, such as heroin and cocaine, and
require unique treatment approaches.
People who develop problems with marijuana may indeed be different
from those who do not, but this phenomenon has been observed with
other substances of abuse. A comparison with alcohol use and depend-
ence provides a case in point. The great majority of Americans have tried
alcohol and continue to drink alcoholic beverages regularly. However,
only an estimated 10 to 15 percent of alcohol drinkers develop problems,
and only some of these problem drinkers seek treatment. This is also
true of those who have tried cocaine or heroin (Anthony, Warner, and
Kessler, 1994).
That said, the experience of dependence on marijuana tends to be less
severe than that observed with cocaine, opiates, and alcohol (Budney,
2006; Budney et al., 1998). On average, individuals with marijuana
dependence meet fewer DSM dependence criteria; the withdrawal expe-
rience is not as dramatic; and the severity of the associated conse-
quences is not as extreme. However, the apparently less severe nature of
marijuana dependence does not necessarily mean that marijuana addic-
tion is easier to overcome. Many factors besides a drug’s physiological
effects—including availability, frequency and pattern of use, perception
of harm, and cost—can contribute to cessation outcomes and the
strength of addiction. The low cost of marijuana, the typical pattern of
multiple daily use by those addicted, the less dramatic consequences,
and ambivalence may increase the difficulty of quitting. Although deter-
mining the relative difficulty of quitting various substances of abuse is
complex, the treatment literature reviewed here suggests that the experi-
ence of marijuana abusers rivals that of those addicted to other sub-
stances.
We have argued elsewhere and reiterate here that animal and human
experiments, as well as the epidemiological and clinical literature, clearly
indicate that marijuana dependence is much more similar to than differ-
ent from other substance dependencies (Budney, 2006; Budney and
Hughes, 2006). As with other substances, sociodemographic, environ-
mental, genetic, and perhaps neurocognitive factors contribute to the
risk of marijuana abuse. Reasons for treatment seeking related to mari-
juana also appear similar to those for other substances (Budney et al.,
1998; Dennis et al., 2002; Stephens, Roffman, and Simpson, 1993), and
the rate of response to treatments appears similar to that observed for
other types of substance dependence (McRae, Budney, and Brady,
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assist in delivery of treatment or continued care.
Equally important to treatment development research
is the pressing need to tackle issues related to dissemi-
nation of effective treatments. Unfortunately, the sub-
stance abuse services delivery system continues to lag far
behind research advances that delineate effective treat-
ment approaches. Serious challenges related to access
and cost impede adoption of important scientific advances
in drug dependence treatment in general. The current
treatment system experiences difficulty recruiting, train-
ing, and retaining treatment staff; inadequate financing
to provide treatment; insufficient treatment availability
to meet demand; and slow adoption of research-based
treatment innovations—all of which contribute to lim-
ited access to the most effective treatments (Carroll and
Rounsaville, 2007; McLellan, Carise, and Kleber, 2003).
The availability of the proven treatments for marijuana
disorders—MET, CBT, and CM—is low, even though
evidence of their efficacy with substance dependence
problems other than marijuana dependence has been
documented for many years. Although the three treat-
ments are mainstream among treatment researchers, few
community-based substance abuse counselors are cur-
rently trained to provide quality MET-CBT, and treat-
ment providers remain ambivalent about CM inter-
ventions because of their cost and CM’s basic premise
of providing incentives for abstinence (Kirby et al., 2006;
Ritter and Cameron, 2007). Treatment services research
must continue to investigate novel, efficient, and effec-
tive methods for treatment dissemination and imple-
mentation.
The good news is that the increased recognition that
marijuana can cause addiction and significant nega-
tive consequences in a subset of users has prompted the
development of marijuana-specific interventions and
treatment materials paralleling those for other substance
use disorders. These advances have increased users’ and
caregivers’ perceptions that it is acceptable to seek and
provide treatment for marijuana use and have contributed
to an increase in the number of individuals requesting
help. Optimistic expectations for enhancements to cur-
rent treatment approaches appear warranted, as our
growing understanding of the principles underlying
behavioral treatments continues to produce innova-
tive applications that demonstrate incremental gains in
efficacy. Rapid advances in the neurobiology associated
with marijuana and the cannabinoid system provide fur-
ther hope for increasingly effective treatment options.
As well, check-up interventions hold promise both for
preventing more severe cases of marijuana dependence
and for increasing therapeutic contacts with mari-
juana abusers who might benefit from treatment.
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RESPONSE: AN INSIDIOUS DEPENDENCE
Dana Mackin, M.A.; Christopher Martin, M.D.; and Jill K. McGavin, Ph.D.
Jill McGavin: What struck me most in
the article (Budney et al., 2007) was the ref-
erence to the rise in treatment admissions
for primary marijuana dependence in the
last 10 years. An increase from 7 to 16
percent of treatment admissions is dramatic.
It makes me wonder what the next 10 or 15
years will bring. I’m anxious to go back and
review the numbers in our treatment admis-
sions for the past couple of years to see if
we’ve already started a shift that has gone
undetected.
Dana Mackin: I was relieved to see that Dr.
Budney and his coauthors addressed the
uniqueness of marijuana addiction. When
I first started reading their article, I was resist-
ant to the idea that marijuana causes depend-
ence, because when we think of addiction
we think of the extreme and striking con-
sequences of methamphetamine or alcohol
abuse. On the other hand, we see the occa-
sional person who has no problem dropping
alcohol or methamphetamine, but cannot
stop smoking pot.
McGavin: Marijuana dependence is usually
a co-occurring addiction and usually not
the more dramatic one. I work primarily
with  veterans.  On  average,  they  are 
in their 50s. About a third are primarily 
alcohol-dependent, a third primarily cocaine-
dependent, and a third primarily heroin-
or opioid-dependent. In only a few cases is
marijuana a primary dependency.
Christopher Martin: My experience is sim-
ilar. However, I do see a fair number of patients
for whom marijuana abuse is a primary issue.
Many of them are young adults who are
involved in daily cannabis abuse and are not
functioning well. They haven’t moved out
of their parents’ homes and are spending a
lot of their time alone, playing video games
and sitting around the house. 
Mackin:Marijuana dependence is definitely
an issue in our clients’ lives. Someone in
recovery who has a heroin or metham-
phetamine addiction is much more likely
to relapse after using pot or taking a drink.
A client of mine said, “You don’t relapse on
your drug of choice; you relapse with pot.
Smoke a joint, and 3 days later, you’ll have
a needle in your arm.” In short, once you
cut out your executive decision-making abil-
ity, relapse is right around the corner.
Martin:That’s consistent with studies with
animal models, which have shown that drugs
have cross-priming properties. Animals
addicted to one substance, when exposed
to another reinforcing drug, will relapse to
use of the original substance. All of these
drugs have similar effects on the mesolim-
bic dopamine system and the reward cir-
cuitry, and it’s not surprising that one pos-
itively reinforcing substance can make it
difficult to stay away from another.
McGavin:Also, if you’re hanging on the cor-
ner, you’re more likely to be passed some-
thing you shouldn’t be using.
Mackin: Right. It puts you back into the
environment, and you don’t learn to deal
with anxiety or craving for your primary
drug without the aid of an external sub-
stance. You’re repeating the same behavior
with a different substance.
Benign reputation, debilitating effects
Mackin: Marijuana’s worst feature is that it
is perceived as benign. Marijuana issues have